Abstract
A qualified nanocarrier for drug delivery to tumor cells based on magnetic mesoporous silica nanoparticles (MMSNs), consisting of Fe3O4 core coated with mesoporous silica and a pH-responsive shell of poly (ethyleneimine) conjugated folic acid was prepared. The nanoparticles were characterized using various techniques including dynamic light scattering (DLS), Brunauer–Emmett–Teller (BET), scanning and transmission electron microscope (SEM and TEM), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), thermogravimetric analysis (TGA), and vibrating sample magnetometer (VSM). Erlotinib as a model anticancer drug was loaded and the release profile was evaluated at pH of 5.5 and 7.4 during 4 days. At lower pH, Erlotinib release amount increased to 63% in comparison with 33% at normal pH. Hemolysis assay results confirmed negligible hemolytic activity of the prepared nanoparticles. No significant toxicity was observed for Erlotinib free MMSNs, while the Erlotinib loaded MMSNs inhibited proliferation of HeLa cell lines. Furthermore, folic acid labeled nanoparticles showed higher cytotoxicity effect on cancerous HeLa cells. Accordingly, the results suggest a controlled targeted drug delivery system to decrease the side effects of anti-cancer drugs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
